Business
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
MASON, Ohio, May 27, 2026--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference.
About this update from Atricure, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/fddfa8d13bbe4c78204d6097ff5847c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M7rl6XiAik42n6J9HNLo4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/fddfa8d13bbe4c78204d6097ff5847c2","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/15ftE4itKFp4lexHXJUoRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/fddfa8d13bbe4c78204d6097ff5847c2","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0ywFDCiFxbHu7e_s1lYutw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/fddfa8d13bbe4c78204d6097ff5847c2","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MASON, Ohio, May 27, 2026--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference.","length":367,"tagName":"p"},{"type":"text","content":"AtriCure’s management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company’s website at https://ir.atricure.com.","length":283,"tagName":"p"},{"type":"text","content":"About AtriCure","length":14,"tagName":"p"},{"type":"text","content":"AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™...